The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.

The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with nearly 17,000 ...

Due to the ongoing shortage of BCG, gemcitabine has been increasingly used for first-line NMIBC therapy. N-803’s ability to activate natural killer and CD8+ T cells, thus the innate immune system, to ...

Using the Decipher Bladder test to determine each tumor’s molecular subtype, researchers found that NMIBC patients with ...

The most common symptom is blood in the urine (hematuria), which may appear pink, red, or brown. Other signs include frequent ...

Exploratory outcome measures include health-related quality of life, overall survival, and biomarker assessments. A broad cross-section of geographically and socioeconomically diverse clinical sites ...

The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with almost 17,000 fatalities. But now, a new gene therapy is giving patients ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

Recent study results show that the single-target DNA methylation test performed with a negative predictive value of 97.6 percent.

The following is a summary of “Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy ...

MRI for the initial staging of MIBC is both feasible and beneficial in reducing treatment delays compared to TURBT, a new study shows.